8. Huntington disease Clinical trials / Disease details
Clinical trials : 229 / Drugs : 193 - (DrugBank : 60) / Drug target genes : 84 - Drug target pathways : 158
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01897896 (ClinicalTrials.gov) | November 12, 2013 | 14/6/2013 | Alternatives for Reducing Chorea in Huntington Disease | An Open-Label, Long Term Safety Study of SD-809 ER in Subjects With Chorea Associated With Huntington Disease | Chorea Associated With Huntington Disease | Drug: SD-809 | Auspex Pharmaceuticals, Inc. | NULL | Completed | 18 Years | N/A | All | 119 | Phase 3 | United States;Australia;Canada |
| 2 | NCT01795859 (ClinicalTrials.gov) | August 5, 2013 | 20/2/2013 | First Time Use of SD-809 in Huntington Disease | A Randomized Double-Blind, Placebo-Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease | Chorea | Drug: SD-809;Drug: Placebo | Teva Pharmaceutical Industries | NULL | Completed | 18 Years | N/A | All | 90 | Phase 3 | United States;Australia;Canada |